NCT00570999撤回2 期
Randomised Placebo-Controlled Double-Blind Phase II Study Applying Palifermin to Improve T-cell Immune Reconstitution After Haploidentical Allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™)
研究概览
简要总结
This is a double blind, placebo controlled clinical trial, where patients with an advanced form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor cell (PBPC) transplant after which they are randomised to receive either placebo or a keratinocyte growth factor (Palifermin or Kepivance®).
The function of Kepivance® is to stimulate the growth of epithelial cells. This drug has also been suggested to have an ability to help improve the reconstitution, or development, of the immune system after the transplantation.
The hypothesis is that the patients T-cell dependent humoral immune response to recall antigen (PrevenarTM) will be higher in in palifermin treated patients than in the placebo control group
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Chemosensitive low/high grade B-NHL or T-NHL, Multiple Myeloma (MM) in partial or complete remission
- •ALL and AML, secondary AML and biphenotypic acute leukemia in complete remission (CR1 or CR2) or PR (only if ≤20% blasts in BM), Myelodysplastic syndrome (MDS)
- •CML in chronic or accelerated phase
- •Osteomyelofibrosis (OMF)
- •Hodgkin lymphoma (HD) in partial or complete remission
- •Age ≥18 years, ≤ 65 years
- •ECOG status ≤2
- •Prior treatment with 3 or less different chemotherapy regimens (not cycles); prior local radiotherapy is allowed except radiation involving the thymus
- •Adequate pulmonary function
- •Left ventricular ejection fraction (LVEF) >30%
- •Haploidentical related donor
- •Failure to find matched related or matched unrelated donor and urgently requiring transplantation
- •Planned conditioning regimen per Aversa or Würzburg protocol
- •Women must be post-menopausal, sterile or use effective contraception and have a negative pregnancy test at study entry (β-HCG neg)
- •Signed informed consent
- •Healthy family member
- •Selection based on typing of HLA-A, B, C, DR loci. Donor must be at least genotypically HLA-A, B, C, DR haploidentical to the patient, but must differ for 2-3 HLA allele(s) on the unshared haplotype
- •Donors must be capable of undergoing leukapheresis, have adequate venous access, and be willing to undergo insertion of a central venous catheter should leukapheresis via peripheral vein be inadequate.
- •Donors must agree to a 2nd donation of PBPCs in case of insufficient CD34+ cell collection or should patient fail to demonstrate sustained engraftment
- •Signed informed consent
排除标准
- •History of or concurrent cancer (< 5 years ago) other than those named in inclusion criteria
- •Primary chemorefractory disease
- •CML in blast crisis
- •MM with no or minor response to previous treatment
- •Prior treatment with palifermin, or other keratinocyte growth factors
- •Documented hypersensitivity to palifermin, E. coli-derived proteins, or any component of the product
- •Documented hypersensitivity to Prevenar vaccine or its components
- •Prior allogeneic or tandem PBPC transplantation (no more than 1 previous autologous transplantation
- •Prior total body irradiation
- •Post thymectomy
- •Major anticipated illness or organ failure incompatible with survival from PBPC transplantation
- •Active chronic skin disease requiring therapy
- •Active inflammatory bowel disease requiring therapy
- •Active uncontrolled infection
- •Sero-positive HIV
- •Pregnancy or breast-feeding
- •Active invasive fungal tissue infection (EORTC criteria)
- •30 days or less since receiving an investigational product or device in another clinical trial
- •Concurrent enrolment in another trial is not permitted unless the purpose is for long-term follow-up/survival data only, or observational only
- •Chronic pancreatitis or history of acute pancreatitis within 1 year prior to transplant
- •Psychiatric disorder associated with incompliance
- •Myocardial infarction less than 3 months pre enrolment or EF <30% as measured in echocardiography/laevoventriculography
- •Infusion of retrovirally or other transduced cells are not permitted.
- •Planned intravenous application of immunoglobulins is contraindicated throughout the study period.
- •Donor lymphocyte infusions are not allowed.
- •A positive HIV or HTLV-1 test or evidence of active/persistent viral hepatitis infection.
- •Evidence of any other active infection
- •Any medical condition (i.e. insulin-dependent diabetes, cardiovascular disorders, chronic inflammatory diseases) posing a health risk for peripheral blood stem cell harvest
- •Hematopoietic or marrow function related disease interfering with the collection of sufficient numbers of normal progenitor cells
- •Pregnancy or breast-feeding
- •Any malignancy besides basal cell epithelioma or cured malignancy < 5 years ago
- •Psychiatric disorder associated with incompliance
研究组 & 干预措施
Arm A
Experimental
Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
干预措施: Palifermin (Drug)
Arm B
Placebo Comparator
Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).
干预措施: Placebo (Other)
结局指标
主要结局
To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™)
时间窗: at study day +270 (20 days after the third Prevenar injection)
次要结局
- To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation(Study days +210, +240, +270)
- To assess disease free survival (DFS) and overall survival (OS), incidence and duration of GvHD, incidence and severity of OM, and incidence and severity of infections(at 2 years)
- To assess drug related safety(at 2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Trial to Assess Safety and Efficacy of Topical MBN-101 in Patients With Moderate/ Severe DFIDiabetic Foot InfectionNCT02723539Microbion Corporation52
进行中（未招募）
2 期
LAM561 With RT and TMZ for Adults With GlioblastomaPrimary GlioblastomaGlioblastoma MultiformeNCT04250922Laminar Pharmaceuticals144
已完成
1 期
Study to Assess the Safety, Pharmacokinetics/Dynamics of DS-1040b in Subjects With Acute Submassive Pulmonary EmbolismThrombotic DiseasePulmonary EmbolismNCT02923115Daiichi Sankyo134
进行中（未招募）
1 期
A phase I (food effect and multiple ascending dose) trial with DNDI-6899Healthy volunteers to test a treatment for Visceral LeishmaniasisInfections and InfestationsISRCTN31974125Drugs for Neglected Diseases Initiative36
已完成
2 期
To access the effect of SCD-044 in treatment of moderate to severe atopic dermatitisatopic dermatitis2024-511615-16-00Sun Pharmaceutical Industries Limited43